Even patients who were never hospitalized for COVID-19 face a heightened risk of cardiovascular issues.

The investigational dual-chamber pacemaker is designed to provide synchronous, beat-by-beat pacing of the right atrium and right ventricle of the heart.

Researchers focused on data from two previous trials to track the impact of IVUS guidance on mortality rates and other key outcomes after three years. 

Evidence shows this technology has the potential to improve care for vulnerable patients with cardiovascular disease.

There have been no incidents at this time, but the device is similar to another Medtronic solution that was recently recalled. 

The new analysis focused on 98 patients who presented with primary mitral regurgitation.

According to the lawsuit, the 23-year-old athlete showed clear signs of Wolff-Parkinson-White syndrome just months before his death. 

The study's authors said some of their findings surprised them. 

It's the first time since 2004 that leadership did not consider financial hurdles as their most pressing issue, according to survey results from the American College of Healthcare Executives.